- Ocuphire Pharma Inc (NASDAQ: OCUP) has screened the first patient in Phase 2 ZETA-1 trial evaluating APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (mild PDR).
- Effects on diabetic macular edema will be explored as a secondary outcome.
- APX3330 is a small molecule oral drug candidate and a first-in-class inhibitor of the transcription factor regulator Ref-1 (reduction-oxidation effector factor-1).
- APX3330 blocks the downstream pathways regulated by Ref-1, including angiogenesis (VEGF) and inflammation (NF-kB), to decrease abnormal activation of both angiogenesis and inflammatory pathways.
- The 100-subject trial is designed to evaluate the efficacy of APX3330 to improve diabetic retinopathy over 24 weeks.
- The study’s primary endpoint will evaluate the percentage of subjects with a more than 2 step improvement on the Diabetic Retinopathy Severity Scale score.
- Secondary endpoints include evaluating central subfield thickness to assess effects on diabetic macular edema, BCVA, safety, and tolerability.
- Price Action: OCUP shares are down 3.07% at $5.68 on the last check Thursday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.